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ABSTRACT 
 
HPV vaccination is routinely recommended for young adult women aged 18-
26 regardless of previous sexual activity or history of HPV-related disease. As of 
2010, only 21% of US women had received ≥1 doses of HPV vaccine.  The objective 
of this study was to describe United States (US) women aged 18-26 who do not 
initiate vaccination and identify a minimum subset of variables to develop a predictive 
model of non-vaccination.  Data from the 2010 National Health Interview Survey 
Adult Cancer Supplement were used to examine US women aged 18-26 (N=1,866).  
Descriptive statistics, univariate procedures, and multivariate logistic regression were 
conducted.  Results indicate that 78% of eligible women did not receive vaccination, 
and 35% of unvaccinated women were not aware of the vaccine.  Eight variables were 
retained for the final model (age aOR=2.93, 95% CI=2.00, 4.30; marital status 
aOR=1.75, 95% CI=1.02, 3.01; live birth in the past 5 years aOR=2.77, 95% CI=1.75, 
4.39, current birth control use aOR=0.45, 95% CI=0.31, 0.64; region aOR=0.50, 95% 
CI=0.31, 0.79; recent doctor’s visit aOR=0.45, 95% CI=0.39-0.84; flu shot receipt 
aOR=0.36, 95% CI=0.24, 0.54; tetanus shot receipt aOR=0.40, 95% CI=0.26, 0.62). 
This model showed good fit to the data (Hosmer-Lemeshow chi-square=14.41(8); 
p=0.07; max rescaled R-square=0.27; c statistic=0.80).  These findings show that older 
age, being married, having children, living in the South, and not receiving other 
preventive health services are associated with non-vaccination. These findings identify 
a subgroup of at-risk women who might benefit from targeted vaccine promotion 
campaigns to increase HPV vaccine uptake. 
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INTRODUCTION 
 
Human papillomavirus (HPV) is the most common sexually transmitted 
infection in the United States (CDCa, 2012).  It is estimated that 80% of sexually 
active females will be exposed to HPV before they reach 50 years of age (Meyers, 
McCrory, Nanda, Bastian, & Matchar, 2000).  Sexually active young women under 25 
are at greatest risk for HPV infection and prevalence of HPV has been shown to be 
highest among women aged 20-24 (Dunne et al., 2007).  Most HPV infections clear on 
their own, but persistent infection with certain types of HPV can cause genital warts, 
cervical cancer, or other cancers of the vagina, anus, head, and neck (Huang, 2008). 
Over 40 HPV types infect the genital area and types are categorized by their 
associated risk to cancer.  High-risk types of HPV (specifically 16 and 18) have been 
associated with 70% of cervical cancers diagnosed worldwide and low risk-types of 
HPV (types 6 and 11) may cause low-grade cervical cell changes and are associated 
with 90% of genital warts (Koutsky, 1997). 
 Two vaccines (GARDASIL® and CERVARIX®) are currently available to 
prevent HPV infection in females.  In 2006, the Food and Drug Administration (FDA) 
approved GARDASIL® (Merck & Co.) for the prevention of cervical cancer, pre-
cancerous lesions, and genital warts in females (FDA, 2006).   GARDASIL® is a 
quadrivalent vaccine (HPV4) protective against HPV types 6, 11, 16, and 18 (Future II 
Study Group, 2007).  In 2009, the FDA approved CERVARIX® (GlaxoSmithKline) 
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for the prevention of cervical cancer (FDAa, 2009).  CERVARIX® (HPV2) is a 
bivalent vaccine protective against high-risk HPV types 16 and 18 (Harper, 2008).  
The HPV2 and HPV4 vaccines are not live vaccines and both are composed of virus-
like particles prepared from L1 capsid proteins (CDC, 2010).  Both vaccines have 
been demonstrated to be highly protective against oncogenic types 16 and 18 and both 
are administered as a three-dose series over six months.  HPV4 was also approved as 
the only HPV vaccine for use in males aged 9-26 for the prevention of genital warts 
and anal cancer (FDA, 2009b; FDA, 2010) 
The Advisory Committee on Immunization Practices (ACIP) has 
recommended routine vaccination with HPV4 for girls aged 11-12 and catch-up 
vaccination for females aged 13-26 since 2007 (Markowitz et al., 2007).  Vaccine 
should ideally be administered before sexual exposure to HPV, but vaccination is also 
recommended for females up to age 26 regardless of previous sexual activity.  ACIP 
recommendations were updated in 2010 after the approval of HPV2 to extend 
recommendation of routine vaccination in these age groups to either HPV4 or HPV2 
(CDC, 2010).  Updated recommendations also included routine use of HPV4 in males.  
Despite ACIP recommendations and new developments in HPV vaccines, uptake of 
HPV4 and HPV2 continues to be low among adolescents aged 13-17 recommended 
for routine ‘catch-up’ and lower for adult males and females aged 18-26 (CDC, 2011; 
CDC, 2012b). 
The Centers for Disease Control and Prevention (CDC) provides national 
estimates of HPV vaccine coverage annually.  CDC monitors national vaccine 
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coverage using two major surveillance systems.  The National Immunization Survey – 
Teen (NIS) (CDC, 2012c) provides coverage estimates for adolescents aged 13-17 and 
the National Health Interview Survey (NHIS) (NCHS, 2012)
 
provides coverage 
estimates for adults.   The 2011 NIS – Teen results indicated 53% of girls aged 13-17 
reported receiving ≥1 dose of the vaccine series and 35% reported receipt of all three 
doses (CDC, 2011).
 
 CDC further reported that HPV vaccine coverage rates are lower 
in younger girls indicating they are not receiving routine vaccination at the 
recommended age of 11 or 12.  Data are limited for boys, but 8% of boys aged 13-17 
had initiated the vaccine series compared to 1% in 2010.  Of young adults, the 2010 
NHIS found that only 21% of females had received ≥1 dose, up from 17% in 2009.   
Less than 1% of males aged 19-26 had received ≥1 dose (CDCb).    
Low uptake among males may be partially explained by the fact that they are a 
new population recommended for vaccination.  Continued low uptake among females 
suggests a need to better understand the specific barriers to HPV vaccination, 
especially among late adolescent and young adult women at highest risk of infection, 
and with lowest coverage of the vaccine.   The national target population for HPV 
vaccination is girls and boys aged 11 or 12 to complete vaccination before sexual 
debut and provide optimal protective benefit.  However, vaccinating young adult 
women between the ages of 18 and 26 has been shown to contribute to reducing 
cervical cancer rates in the population while providing a strong clinical benefit to 
individual females, even if they are already sexually active (Harper & Paavonen, 
2008; Adams, Jasani, & Fiander, 2009).  
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Previous research has demonstrated that women who have previously been 
exposed to HPV would still benefit from vaccination because it is unlikely that they 
would have been exposed to all HPV types covered in the vaccine.  In a study of 3,276 
women aged 19-24, less than 1% were co-infected with both high-risk types 16 and 
18, and no women were found to be infected with all four types (Dempsey, 
Gebremariam, Koutsky, & Manhart, 2008).  Recent research also suggests that HPV 
vaccines induce high virus-neutralizing antibodies in young adult women and provides 
high protective efficacy comparable to the protective effect in young teenage girls 
(Westra et al., 2011).
  
HPV vaccines are prophylactic, not therapeutic, and while only 
women negative to vaccine-specific HPV types would optimally benefit from 
vaccination, clinical and cost-effectiveness research support comprehensive 
vaccination for women up to age 26 (Kim, Orethndahl, & Goldie, 2009).
   
However, 
women in this age range are more likely to experience significant barriers to accessing 
the vaccine.  To increase vaccine uptake among young adult women, further study is 
needed to better understand person factors associated with vaccine initiation or non-
vaccination among women aged 18 to 26.        
More data have become available over the past few years to suggest 
demographic, socioeconomic, healthcare, and knowledge characteristics are 
significantly related to young adult women receiving the HPV vaccine. Reports from 
the NHIS and NIS-Teen surveys indicated differences in vaccine uptake by 
demographic and socio-economic characteristics.  For example, among adolescents in 
the 2011 NIS - Teen, black adolescents were less likely to complete the vaccine series 
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than whites, and completion was lower among adolescents living below the poverty 
line (CDC, 2011).  However, initiation of the vaccine series was higher among 
Hispanics than whites.  There are less available data to describe females over 17 years 
of age, but the 2010 NHIS reported differences based on ethnicity.  Hispanic women 
had less coverage than non-Hispanic whites, but no other racial or ethnic differences 
were observed (CDCb, 2012).  An early study of vaccine uptake reported that vaccine 
initiation among women aged 18-26 in the 2007 National Immunization Survey was 
positively associated with higher socioeconomic status, not being married, and having 
health insurance coverage (Jain et al., 2007).   In a university-based clinic system, 
vaccine series initiation among young adult women was reported to be negatively 
associated with public insurance, white race, and older age (Dempsey, Cohn, Dalton, 
& Ruffin, 2011).   Socio-demographic factors such as age, race, ethnicity, and 
socioeconomic status have also been associated with increased knowledge about HPV 
and the HPV vaccine
 
(Ragin et al., 2009) and HPV-related knowledge has been shown 
to be another predictor of HPV vaccine initiation among young women (Allen et al., 
2009; Licht et al., 2010).  A study examining reasons for non-vaccination among 
young women in a large administrative claims database implied improved educational 
interventions about HPV and the vaccine may improve uptake.  The authors reported 
the main reasons for non-vaccination were being married or in a monogamous 
relationship, believing the vaccine was too new, concern about side effects, and 
uncertainty about insurance coverage and that a physician’s recommendation for  
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vaccination resulted in a 4-fold greater likelihood of vaccination (Zimet, Weiss, 
Rosenthal, Good, & Vichin, 2010; Rosenthal, Weiss, Zimet, Good, & Vichnin, 2011).  
Increasing vaccine initiation among young adult women is a necessary 
component of the national HPV vaccination program.  Vaccine coverage is low for 
most recommended adult vaccines, and far below national targets (CDCb, 2012).  
Improvement in vaccine uptake among adults is needed to reduce morbidity and 
mortality of vaccine-preventable diseases such as HPV.  More research to better 
describe and understand this distinct group of women and their personal reasons for 
non-vaccination would benefit targeted interventions for young adult women.  The 
objectives of this study were to describe women aged 18-26 in a recent national 
sample who report non-vaccination against HPV, determine predictors of HPV non-
vaccination, and identify a minimum subset of variables to develop a predictive model 
of non-vaccination.   
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METHOD 
 
Design Overview and Sample Selection 
National Health Interview Survey  
This study used data collected by the 2010 National Health Interview Surveys 
(NHIS) to develop a prediction model, and then used data from the 2011 NHIS to 
examine the robustness of significant multivariate-adjusted predictors an independent 
sample.  The National Health Interview Survey (NHIS) is a primary source of 
information on the health of the civilian non-institutionalized population of the United 
States.  It is considered a major data collection program of the National Center for 
Health Statistics (Centers for Disease Control and Prevention) and used by the 
Department of Health and Human Services to monitor health trends, track progress 
towards reaching national health objectives, and provide national estimates.  Due to 
the collection of many demographic and socio-economic variables, NHIS data are 
frequently used by public health researchers for epidemiological studies to identify 
and describe groups at higher risk for certain health conditions and to examine barriers 
to health care access and utilization.  More information about the National Health 
Interview Surveys is available here: http://www.cdc.gov/nchs/nhis.htm. 
NHIS Sampling Design  
NHIS is a cross-sectional interview survey conducted annually among a 
nationally representative sample of households.  NHIS uses a stratified, multistage, 
cluster sampling design.  Black, Hispanic, and Asian persons are intentionally 
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oversampled to ensure adequate representation in the sample.  Institutionalized 
individuals are excluded; examples of these individuals include patients in long-term 
care facilities, persons on active duty with the Armed Forces, and incarcerated 
persons.  Basic person weights are used to analyze person record data and person 
weights are adjusted to Census control totals for sex, age, and race/ethnicity 
populations.  NHIS data are for public use and the data sets, documentation, survey 
instruments, and sample statements for various statistical software packages are 
available for download online.   
Data collection is continuous through the year and a probability sample of the 
US non-institutionalized population is interviewed each week.  Face-to-face 
interviews are conducted by personnel from the U.S. Bureau of Census using 
computer-assisted personal interviewing.  One adult from each household is randomly 
selected to self-report responses for the Sample Adult File.   For the Family File, all 
household members 17 years of age or older are invited to participate and respond for 
themselves; a responsible adult household member (18 years or older) is allowed to 
provide responses for children and other adults not present at the time of interview.  
The questionnaire contains the “core” questionnaire which includes three components 
(Family, Sample Adult, and Sample Child) to cover a broad range of health and 
demographic items, including vaccine coverage.  A “supplement” questionnaire may 
be included in some years of the NHIS to monitor current health issues.  The core 
questionnaire consistently includes questions specific to vaccination [e.g. Hepatitis A 
and B, Influenza, pneumococcal polysaccharides vaccine (PPV), Herpes Zoster, 
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Tetanus-Diphtheria-Pertussis (Tdap)] to inform national coverage estimates.   In 2008, 
new questions were added to the NHIS to assess vaccine coverage related to the recent 
approval and ACIP recommendations for HPV vaccination.  In 2010, an Adult Cancer 
File Supplement was included as the yearly supplement to examine adult cancers 
including cervical cancer.  This file includes additional questions specific to cervical 
screening history, HPV vaccination history, attitudes about HPV vaccination, and 
reasons for non-vaccination.    
Design Overview and Sample Selection   
Initial analyses were based on 27,157 adults (18 years or older) from the 2010 
Adult Cancer File.  The sample for analysis was restricted to a subset of late 
adolescent women aged 18-26 (N=1,866) who reported yes or no to the survey 
question, “ever received the HPV shot or vaccine?”  The Adult Cancer Files was then 
merged with the Person and Adult Files to obtain additional-level demographic and 
health information.  All data used for analysis was obtained from public-use data files 
made available by the National Center for Health Statistics.  All personally-identifying 
information is removed from the data files prior to data release.  This study met 
exemption criteria for oversight by the University of Rhode Island Institutional 
Review Board.  
Measures 
The dichotomous outcome variable was initiation of the HPV vaccine series 
defined as receipt of ≥1 doses of the HPV vaccine.  HPV vaccine initiation is defined 
by the NHIS variable name SHTHPV1 (“ever received the HPV shot or vaccine”).  
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Since the outcome of interest was non-initiation of vaccination, a response of no was 
coded as 1 (n=1,458; 72.50%) and a response of yes was coded as 0 (n=408; 20.29%).  
All other responses including doctor refused when asked (n=1; 0.05%), refused (n=7; 
0.35%), not ascertained (n=119; 5.9%) and don’t know (n=18; 0.90%) were excluded 
from the analysis.   
The predictor variables were derived from the Adult, Person, or Adult Cancer 
Files.  The predictor variables of interest were selected based on previous research 
describing factors associated with HPV vaccine receipt.  The data dictionary (variable 
summary and frequency reports of the Adult Cancer, Person, and Adult Files) were 
then scanned to match factors related to variables in the questionnaire.  The 2010 
NHIS Survey Description document was also consulted for analytic recommendations 
regarding variable recodes and assessment of commonly used variables such as public 
health insurance and income (NCHS, 2010).  The large number of predictor variables 
selected for analysis were grouped into four domains to establish an organizing 
framework for the study: 1) demographic, 2) socioeconomic, 3) health services 
utilization, and 4) HPV awareness.   
  Thirty-nine variables were identified for exploratory analysis and grouped into 
categories.  Variables and their original response categories are presented in Table 1.  
The goal of this exploratory analysis was to examine the characteristics of each 
variable, determine if the variable could potentially be used in a modeling analysis, 
and, if necessary, prepare potential variables for bivariate tests of association.  Means 
and frequencies of each variable were examined and then crosstabs between the 
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potential predictor and the outcome variable were conducted to examine cell size.  To 
ensure reliable estimates, variables were required to contain 30 or more observations 
per cell (NCHS, 2010).  Variables with small cell counts were then manipulated to 
facilitate statistical analyses.  For example, categorical variables with multiple levels 
may have been collapsed to increase cell counts and examine the relationship between 
predictor and outcome.  
  Initial demographic variables included age (categorized to 18-21, 22-25, and 
26), race recoded (recoded to white, non-white), ethnicity (Hispanic, not Hispanic), 
marital status (recoded to married, not married), primary language (recoded to 
English, non-English), born in US (yes, no), US census region (South, Northeast, 
Midwest, and West), and given birth in the past 5 years (yes, no).  Assessment of 
parametric form was conducted for the continuous variable of age (Hosmer & 
Lemeshow, 2000).  To examine the association of age to vaccine receipt, age was 
categorized into 1 year intervals from 18-26 using 18 as the reference group and then 
plotted against the log odds of vaccine initiation.  The plot demonstrated a nonlinear 
relationship and suggested three previously specified levels for age (18-21, 22-25, and 
26). 
Socioeconomic variables included no insurance coverage (yes, no), private 
insurance coverage (yes, no), public insurance coverage (yes, no) including Medicare, 
Medicaid, and other state or government plans as described in the 2010 NHIS Survey 
Description, education (recoded to college education yes or no), and income (recoded 
to <$20,000, $20,000-$34,999, and >$35,000).  College education was also examined 
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as a multilevel categorical predictor with four levels: less than high school, high 
school, some college, college or higher.   
Health utilization variables included ever receiving a Pap test (yes, no), 
abnormal Pap test results (yes, no), HPV diagnosis (yes, no), reported health status 
(recoded to excellent/very good, good/fair/poor), has usual place of care (yes, no), 
place to go when sick (recoded to doctor’s office or clinic, other), seen/talked to a 
doctor in past 12 months (yes, no), seen/talked to an OB/GYN in past 12 months (yes, 
no), currently using birth control (yes, no), receipt of flu shot in the past 12 months 
(yes, no), receipt of Hepatitis A vaccine (yes, no), receipt of Hepatitis B vaccine (yes, 
no), receipt of tetanus shot in the past 10 years (yes, no), had an STD test in past 5 
years (yes, no), saw a doctor for an STD (yes, no), and ever been tested for HIV (yes, 
no).   
HPV-related knowledge variables included ever heard of HPV (yes, no) and 
ever heard of the HPV vaccine (yes, no).  Other HPV-related attitudes and awareness 
items included in the 2010 Adult Cancer Supplement that were exclusive to women 
who did not initiate vaccination were examined for descriptive purposes (e.g. interest 
in the HPV vaccine, reasons for non-vaccination, and willingness to get the vaccine at 
lower cost).   
Statistical Analyses 
Step 1: Variable Selection 
 The goal of this analysis was to identify the variables significantly associated 
with HPV vaccine initiation in simple bivariate analyses, and retain these variables for 
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model development.  Associations between the outcome and each predictor variable 
were examined using t tests for continuous variables or chi-square tests of 
independence for categorical variables.  Variables were retained for further analysis if 
associations were significant at the p<.20 level based on the Wald chi-square statistic, 
provided more than 30 observations per cell, or if they are supported through theory or 
empirical research.  The 0.20 level was chosen as a screening criterion for variable 
selection rather than the traditional 0.05 level because this cut-off may fail to identify 
variables that would be important when combined in a multivariate model (Hosmer & 
Lemeshow, 2000).   
Step 2:  Unadjusted Odds Ratios 
 Variables that were retained based on bivariate associations were examined 
further to assess the strength of their relationship to the outcome.  Univariate logistic 
regressions, unadjusted odds ratios, and 95% confidence intervals were calculated for 
each predictor.  Variables significant at the traditional p<.05 with standard error of the 
prevalence estimate <30% were considered to be strong predictors and selected for 
retention in further modeling analyses (NCHS, 2006).  At this stage, collinearity 
diagnostics in each group were reviewed.  Variables with a condition index over 30, 
with a variance inflation factor (VIF) over 10, or pairs that explain more than 50% of 
the variance were to be dropped from the analysis (Menard, 1995).  Finally, potential 
interaction terms between significant variables in each variable grouping were 
examined.  Interaction terms were evaluated to ensure they satisfied the hierarchy 
principle recommended by Kleinbaum and Klein (Kleinbaum & Klein, 2002).  The 
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hierarchy principle states that all lower-order components of the model must be 
retained if there is a significant higher-order interaction term.   In other words, it 
would be inappropriate to remove a main effects variable from the model if the model 
contains an interaction term involving that variable.  
Step 3: Separate Multivariable Logistic Regression Models 
 Variables that met criteria for retention in the last step were entered into four 
separate multiple logistic regression models based on groups.  This approach allows 
related significant variables to compete with each other to identify the strongest 
predictors, thereby facilitating the selection of a minimum subset of variables to 
predict the outcome (Snyder, Willey, McKenna, Foley & Coleman, 2005).  Variables 
from the group-specific models that were significant at the p<.05 level were retained 
for inclusion in the final model. 
Step 4: Final Model 
The retained predictors were tested in a final model to identify the most 
parsimonious equation to predict HPV non-vaccination.  After the main effects were 
identified, interaction effects were examined.  The results of the modeling approach 
were confirmed by backwards selection procedure.  Multivariate-adjusted variables 
significant at the p<.05 level were considered final predictors and the model was 
judged to fit the data by a nonsignificant Hosmer-Lemeshow goodness of fit test at the 
0.05 level of significance, and by the C-statistic.  Values for the C-statistic range from 
0.5 to 1.0 and a value of 0.5 indicates the model is no better than chance at predicting 
group membership.  Typically, values higher than 0.7 indicate acceptable 
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discrimination, values higher than 0.8 indicate excellent discrimination, and values 
higher than 0.9 indicate outstanding discrimination (Hosmer & Lemeshow, 2000). 
Area under the curve, sensitivity, specificity, and max rescaled R-square were also 
presented to display the predictive power of the logistic model.  After the model was 
specified, its predictive capacity was tested by testing the model in the 2011 NHIS 
dataset as a confirmatory analysis. 
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RESULTS 
 
 
Sample Characteristics 
 
 Of women aged 18-26 in this sample, 78.1% (n=1,458) did not initiate HPV 
vaccination.  Summary characteristics of non-vaccinated women including select 
demographics, socioeconomic, and health utilization variables are presented in Table 
2.  Mean age was 22.6 years (SD=2.4).  The majority were white (49.6%), unmarried 
(78.2%), had health insurance (75.4%), and had at least some college education 
(57.5%).   
Reasons for non-vaccination, vaccine awareness, and other HPV-vaccine 
related attitudes are presented in Table 3.  Reasons to not initiate vaccination varied.  
Of unvaccinated women, 34.6% reported they had not heard of the HPV vaccine and 
62.9% reported they were not interested in receiving it.  The three main reasons for not 
receiving the vaccine were “does not need vaccine” (40.4%), “don’t know enough 
about the vaccine” (13.5%), and “worried about safety of the vaccine” (10.8%).  
Summary characteristics of the other women who received at least one dose of the 
vaccine series (n=408) are presented in Table 4. 
Bivariate Results     
 Table 5 summarizes the results of preliminary statistical tests to screen a large 
number of potential predictor variables.   Most items that were related to 
demographics, socioeconomic, and health services utilization were significantly 
associated with vaccine initiation.  Nine variables (full-time work, previous STD test, 
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ever heard of HPV vaccine, five health insurance variables related to public insurance, 
and one item related to insurance ineligibility) could not be examined statistically 
because of small counts.  Variables that met established criteria for retention (e.g. 
significant univariate odds ratios) were examined in category-specific logistic 
regression models. 
Model 1: Demographics Variables 
 Age, region, race, ethnicity, primary language, marital status, born in the US, 
and live birth in the past 5 years were all significant independent predictors of vaccine 
initiation.  Age, region, marital status, and live birth in the past 5 years remained 
statistically significant when adjusted for other variables.  Table 6 presents the 
unadjusted and adjusted odds ratios and 95% confidence levels.  In multivariate 
analyses, older age, 22-25 years (aOR=2.30, 95% CI=1.79, 2.95) and 26 years 
(aOR=1.83, 95% CI=1.25, 2.69), being married (aOR=1.49, 95% CI=1.04, 2.14), and 
having had a live birth in the past 5 years (aOR=1.81, 95% CI=1.36, 2.40) were 
associated with higher odds, or increased risk, of non-vaccination.  Living in the 
Midwest (aOR=0.73, 95% CI=0.54, 0.99) or West (aOR=0.67, 95% CI=0.49, 0.90) 
was associated with lower odds of being in the non-vaccinated group.  Potential 
interactions were assessed at the univariate level, and then adjusted for multivariate 
analyses.  At the univariate level, there were significant interactions between race and 
age of 22-25 years (p<.0001), race and age of 26 years (p=.03), marital status and age 
of 22-25 years (p<.0001), live birth and age of 22 and 25 years (p<.0001), live birth 
and age of 26 years (p=.007), live birth and marital status (p<.0001), live birth and 
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race (p<.0001), race and Midwest (p=.02), and race and West (p=.04).  No interaction 
terms remained significant in the multivariate model.  Multicollinearity was also 
assessed and no multicollinearity was detected at this level.  The model fit the data 
well as evidenced by a nonsignificant Hosmer and Lemeshow goodness of fit test (chi-
square=1.55, Pr>chi-square=0.67). 
Model 2: Socioeconomic Variables 
 In univariate analyses, no insurance coverage, private insurance coverage, 
Medicaid coverage, and college education were significant independent predictors of 
vaccine initiation.  College education and no insurance coverage remained statistically 
significant multivariate-adjusted predictors when entered into the category-specific 
model.  Table 7 presents the unadjusted and adjusted odds ratios and 95% confidence 
intervals.  In multivariate analyses, no insurance coverage (aOR=1.86, 95% CI=1.16, 
3.00) was associated with increased risk of non-vaccination, while having a college 
education (aOR=0.74, 95% CI=0.75, 0.95) was associated with decreased risk of being 
non-vaccinated.  Education and insurance coverage showed a significant interaction at 
the univariate level (p=.01), but it was not demonstrated to be significant at the 
multivariate level.  Multicollinearity diagnostic procedures were also conducted and 
no multicollinearity between variables was detected.  The model fit the data well as 
evidenced by a nonsignificant Hosmer and Lemeshow goodness of fit test (chi-
square=1.48, Pr>chi-square=.82). 
Model 3: Health Services Utilization Variables 
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 In univariate analyses, tetanus shot in the past 10 years, Hepatitis A vaccine, 
Hepatitis B vaccine, flu shot in the past year, current birth control use, having been 
diagnosed with HPV, doctor’s visit within the past 12 months, and having a usual 
place of care were all significant independent predictors of non-vaccination.  Tetanus 
shot, flu shot, current birth control use, doctor’s visit in the past year, and usual place 
of care remained statistically significant in multivariate analysis.  Unadjusted and 
adjusted odds ratios with 95% confidence intervals are presented in Table 8.  
Multivariate results indicated that tetanus shot (aOR=0.45, 95% CI=0.27, 0.75), flu 
shot (aOR=0.52, 95% CI=0.34, 0.78), current birth control use (aOR=0.47, 95% 
CI=0.32, 0.69), doctor’s visit in past year (aOR=0.56, 95% CI=0.32, 0.69), and usual 
place of care (aOR=0.51, 95% CI=0.28, 0.94) were associated with decreased odds of 
being non-vaccinated.  Significant interactions at the univariate level were found 
between tetanus shot and flu shot (p<.0001), usual place of care and doctor’s visit in 
the past year (p<.0001), and birth control pills and doctor’s visit in the past year 
(p<.0001).   No interaction terms were determined to be multivariate-adjusted 
predictors and no multicollinearity was detected in this category.  The model fit the 
data well as evidenced by a nonsignificant Hosmer and Lemeshow goodness of fit test 
(chi-square=12.32, Pr>chi-square=0.13). 
Model 4: HPV Awareness 
 Two variables were initially examined for this model.  The variable “heard of 
HPV vaccine” was eliminated due to small cell count (Table 9).  Having heard of HPV 
was associated with decreased odds of being in the non-vaccinated group (OR=0.24, 
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95% CI=0.16, 0.35), but was not chosen for inclusion in the final model due to 
potential error (e.g. women who report HPV vaccination, but have not heard of HPV). 
Final Model 
 Significant variables identified in category-specific logistic models were 
entered into one final model.  The nonsignificant variables from the category-specific 
models were deleted to achieve the aim of specifying the most parsimonious model 
able to predict non-vaccination.  Eleven variables included in the preliminary model 
included age, no insurance coverage, marital status, college education, usual place of 
care, live birth in the past 5 years, birth control, doctor’s visit in past year, flu shot in 
the past year, and tetanus shot in past 10 years (Table 10).  In multivariate analysis, no 
insurance coverage, college education, and usual place of care did not remain 
statistically significant.  To confirm this approach, a backwards selection procedure 
was conducted and results supported the deletion of usual place of care and college 
education, but supported the retention of insurance coverage in the model.  To address 
the discordance in results, two models were specified and compared using the 
likelihood ratio test (Kleinbaum & Klein, 2002).  Both models excluded college 
education and usual place of care, but the first model excluded no insurance coverage, 
and the second model included no insurance coverage.  Results of the likelihood ratio 
test indicated the first model that excluded insurance coverage fit the data better 
(deviance difference 1026.69-1025.04=1.65, DF difference 12-11=1, χ2(1)=3.84).  
Since the deviance difference is less than the chi-square critical value, the model with 
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more parameters is not an improvement over the partial model.   Both models are 
presented here. 
 The first model was developed according to the model-building approach 
described previously, and without the variable of insurance coverage.  This model 
included eight significant multivariate-adjusted predictors of non-vaccination (Table 
11).  Variables significantly associated with increased odds of non-vaccination 
included older age (22-25 years compared to 18-22 years) (aOR=2.93, 95% CI=2.00, 
4.30), being married (aOR=1.75, 95% CI=1.02, 3.01) and having a live birth in the 
past 5 years (aOR=2.77, 95% CI=1.75, 4.39).  Variables significantly associated with 
decreased odds of being in the non-vaccination group included living in the West as 
compared to the South (aOR=0.50, 95% CI=0.31, 0.79), currently being on birth 
control (aOR=0.45, 95% CI=0.31, 0.64), flu shot receipt in past year (aOR=0.36, 95% 
CI=0.24, 0.54), tetanus shot in the past 10 years (aOR=0.41, 95% CI=0.26, 0.62), and 
seeing a doctor in the past year (aOR=0.57, 95% CI=0.39, 0.84).  Multiple potential 
interaction terms were assessed.  Five interaction terms were significant at the 
univariate level: 22-25 years of age and live birth (p<.0001), 22-25 years of age and 
marital status (p<.0001), 22-25 years of age and Northeast (p=.002), 22-25 years of 
age and West (p=.003), marital status and live birth (p<.0001). No interaction terms 
were significant as multivariate-adjusted predictors.  No multicollinearity was detected 
(Table 12).  This model showed good fit to the data as evidenced by a nonsignificant 
Hosmer & Lemeshow goodness of fit test (chi-square=14.41(8); Pr>chi-square=.07) 
and a significant model chi-square of 193.30(11); Pr>chi-square=<.0001.  The c-
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statistic was 0.795 indicating a strong prediction capacity.  Max rescaled R-square was 
0.268.  Area under the curve is presented in Figure 2 and classification tables are 
presented in Table 13. 
 The second model included insurance coverage based on the backwards 
selection procedure results (Table 14).  This model included nine significant 
multivariate-adjusted predictors of non-vaccination.  Variables associated with 
increased odds of non-vaccination included older age (22-25 years compared to 18-22 
years) (aOR=2.91, 95% CI=1.99, 4.27), being married (aOR=1.81, 95% CI=1.06, 
3.17), having a live birth in the past 5 years (aOR=2.67, 95% CI=1.69, 4.23), and not 
having insurance coverage (aOR=1.70, 95% CI=1.06, 2.72).  Variables associated 
with protection against being in the non-vaccination group included living in the West 
(as compared to South) (aOR=0.49, 95% CI=0.31, 0.78), currently being on birth 
control (aOR=0.46, 95% CI=0.32, 0.66), flu shot receipt in past year (aOR=0.36, 95% 
CI=0.24, 0.54), tetanus shot in the past 10 years (aOR=0.42, 95% CI=0.27, 0.66), and 
seeing a doctor in the past year (aOR=0.63, 95% CI=0.43, 0.93).  Six interaction terms 
were significant at the univariate level: 22-25 years of age and live birth (p<.0001), 
22-25 years of age and marital status (p<.0001), 22-25 years of age and Northeast 
(p=.002), 22-25 years of age and West (p=.003), no insurance coverage and Midwest 
(p=.003), and marital status and live birth (p<.0001).  No interaction terms were 
significant as multivariate-adjusted predictors.  Multicollinearity was assessed and no 
multicollinearity was detected (Table 15).  This model showed also good fit to the data 
as evidenced by a nonsignificant Hosmer & Lemeshow goodness of fit test (chi-
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square=10.24(8); Pr>chi-square=.24) and a significant model chi-square of 
198.05(12); Pr>chi-square=<.0001.  The c-statistic was 0.797 indicating a strong 
prediction capacity (Hosmer & Lemeshow, 2000).  Max rescaled R-square was 0.27. 
Area under the curve is presented in Figure 3 and classification tables are presented in 
Table 16. 
Cross-Validation Model: 2011 National Health Interview Survey 
 To further examine the robustness of the significant predictors in final model, 
these predictors were tested in an independent sample using a reduced set of variables.  
The 2011 National Health Interview Survey is structured to allow analysis across 
multiple years.  Six of the eight significant multivariate-adjusted predictors from the 
final model were included in the 2011 person-level files; live birth in the past 5 years 
and current birth control use were exclusive to the 2010 Adult Cancer File Supplement 
and not available for 2011-level analysis.  Parametric assessment for age was assessed 
and revealed a non-linear pattern with three distinct age groups (18-24, 25, and 26).  In 
2011, 71.5% (n=1,655) women reported not receiving the HPV vaccine and 28.4% 
(n=659) reported receipt of ≥1 dose.  Five variables were significant multivariate-
adjusted predictors of non-vaccination (Table 17); region was the only variable that 
was not strictly statistically-significant when adjusted for other variables, but one-level 
(West) was borderline significant (p=.05).  Variables that showed increased risk of 
non-vaccination included age (25 years) (aOR=1.61, 95% CI=1.19, 2.19) and age (26 
years) (aOR=2.42, 95% CI=1.70, 3.43), and marital status (aOR=2.38, 95% CI=1.78, 
3.19).  Variables protective against non-vaccination included receipt of flu vaccine in 
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past year (aOR=0.60, 95% CI=0.49, 0.75), receipt of tetanus shot in past 10 years 
(aOR=0.46, 95% CI=0.36, 0.57), and seeing a doctor within the past year (aOR=0.62, 
95% CI=0.51, 0.77).  Multicollinearity was assessed using the procedure described 
previously and no multicollinearity was detected (Table 18).  This model showed a 
good fit to the data as evidenced by a nonsignificant Hosmer-Lemeshow goodness of 
fit (chi-square=2.80(8); Pr>chi-square=.94), a c-statistic of .696, and a max re-scaled 
R-square of .13.  Area under the curve is presented in Figure 5 and classification tables 
are presented in Table 19. 
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DISCUSSION 
 
 Seven years after the approval of the first HPV vaccine, US women aged 18-26 
continue to have lower HPV vaccine coverage compared to adolescent girls.  The goal 
of this study was to describe US women who have not initiated the vaccine series, 
examine their reasons for non-vaccination, and identify predictors of non-vaccination.  
We found that 78% of women recommended for routine vaccination did not receive 
the vaccine, and 35% of unvaccinated women had not ever heard of the vaccine.  
Current findings indicate that non-vaccinated women differed from vaccinated women 
on several key socio-demographic and healthcare utilization variables.  Women who 
were older, married, and had children were at higher risk for being unvaccinated, 
while women who lived in the West, had a recent doctor’s visit, and practiced 
preventative health behaviors such as using birth control, receiving a yearly flu 
vaccine, or recent tetanus vaccine were more likely to be vaccinated.  These findings 
suggest that there are subgroups of 18-26 year old women at higher risk for non-
vaccination, and findings may inform targeted interventions to increase vaccine 
delivery to these subgroups. 
 In our study, older age was the strongest predictor of non-vaccination status.  
Being 22-25 years old was associated with a nearly three-fold increase in the odds of 
being unvaccinated compared to being 18-21 years old.  Previous research examining 
HPV vaccine uptake in young adult women has reliably demonstrated younger age to 
be strongly associated with vaccine initiation (Licht, 2010; Dempsey, 2011; Chao, 
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Velicer, Slezak & Jacobsen, 2010; Rosenthal, 2011; Tiro et al., 2012; Marchard, 
Glenn, & Bastani, 2013).   Younger age may be a protective factor against non-
vaccination due to the increased likelihood that younger women have access to health 
care and may still qualify for “safety net” vaccine delivery programs such as the 
Vaccine For Children (VFC) program (Marchard, 2013; Dempsey 2008).  The VFC 
program provides free vaccines, including HPV vaccines, to low-income, uninsured 
children and adolescents aged 18 years or younger.  Younger women are also more 
likely to be enrolled as full-time college students and are generally required to be 
covered under their college health plan or parental health insurance.  Increased vaccine 
coverage of college-aged women may be associated with receipt of other vaccinations 
due to pre-matriculation vaccine requirements, parental influence, and access to the 
HPV vaccine through college health centers (Licht, 2010).   
Women outside of college, or uninsured older women, can face significant 
financial barriers to accessing the vaccine.  Of unvaccinated women in our sample 
who were asked if they would receive the vaccine if it was free or lower cost, 96% 
said yes.  HPV vaccines are the most expensive vaccines to date with retail costs 
averaging about $130 per dose ($390 for full series) (CDC, 2012d).  It has been 
previously demonstrated that young adults aged 18-26 in the US are at high-risk for 
being uninsured (or under-insured to cover vaccines) when they reach the age where 
they cease to be covered under parental insurance, and have not yet established their 
own work-based health insurance (Park, Mulye, Adams, Brindis, & Irwin, 2007; 
Nicholson et al., 2009).  In our study, not having health insurance was a significant 
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univariate predictor of non-vaccination, though it dropped out of the final model.  
Further exploration of this variable is warranted.  Findings from other national 
probability samples have indicated insurance coverage to be a univariate and 
multivariate-adjusted predictor of vaccination.  An early 2007 analysis of adult women 
in the National Immunization Survey (Jain, 2007) indicated that insurance coverage 
was positively associated with vaccine uptake and a 2010 analysis of the National 
Family Growth Survey found insurance coverage to be significantly associated with 
vaccine initiation regardless of age (Liddon, Leichliter, & Markowitz, 2012).  Further 
examination of current vaccine assistance programs for uninsured young people is 
needed to examine how these programs can better respond to national vaccine needs 
and gaps.  Marchand et al. (2012) suggest catch-up vaccination rates among uninsured, 
low-income women may be increased by revising age inclusion criteria for adolescent 
vaccine safety-net programs to consider young adults up to age 26, as well as 
encouraging community health centers to participate in manufacturer-based cost 
assistance programs (Merck’s Patient Assistance Program and GlaxoSmithKline’s 
Cervarix program).   
In addition to age, we found demographic variables such as marital status and 
having children to be significant risk factors for non-vaccination.  Married women 
were 84% more likely to be unvaccinated compared to unmarried women; women 
who had children were more than twice as likely to be unvaccinated compared to 
women without children.  These findings may reflect a belief among women, and 
potentially among their providers, that they are not at risk for HPV or would not 
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benefit from vaccination.  In a 2010 study of young women’s reasons for non-
vaccination, the authors found that 55% of women reported they did not initiate 
vaccination because they were married or in a monogamous relationship (Zimet, 
2010).   A perceived lack of need due to perceived low risk (e.g. being in a committed 
relationship, few or no sexual partners) has been shown to be a predictor of non-
vaccination in other population surveys (Grant, Kravitz-Wirtz, Breen, Tiro, & Tsui, 
2009; Jain, 2007).  We also found that 63% of unvaccinated women reported they 
were not interested in receiving the vaccine.  When asked about their main reason for 
not receiving the vaccine, 44% of women reported reason they did not need it. Despite 
evidence to support universal vaccine recommendations for this age group, some 
women may incorrectly think they do not need the vaccine because they are low risk, 
already infected with HPV, or too old to receive any protective benefit.  Routine use of 
the HPV vaccine in catch-up women, even if they were already sexually active, was 
recommended over a targeted risk-factor approach due to the ubiquitous nature of 
HPV infection and data showing that it is unlikely that women exposed to one type of 
HPV have been exposed to all types covered in the vaccine.  Thus, older women can 
obtain partial clinical benefit from vaccination after sexual debut, or after exposure to 
HPV.  Misconceptions regarding vulnerability to HPV disease and HPV vaccine 
efficacy reflect important gaps in young women’s HPV-related knowledge, and efforts 
to increase vaccine uptake would benefit from information-driven campaigns that aim 
to correct key observed misperceptions.  While general knowledge about HPV, the 
association between HPV and cervical cancer, and the availability of a preventive 
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vaccine is high among young women, more complex information about HPV 
transmission, screening, other disease consequences have been demonstrated to be low 
in samples of young women (Allen, 2009; Licht et al., 2010; Lopez & McMahan, 
2007; Sandfort & Pleasant, 2009; Gerend & Magloire, 2008).  Knowledge-based 
campaigns may benefit from providing additional clinical information about HPV 
transmission, HPV disease, and prevention to inform more accurate risk perceptions 
for HPV.  
 Additionally, disagreements among national leaders about vaccine 
recommendations for 18-26 year old women can contribute to public confusion or 
misperceptions of vaccine benefit.  While ACIP recommends universal vaccination, 
the American Cancer Society (ACS) cites insufficient evidence to recommend 
vaccination in all 19-26 year old females (Saslow et al., 2007).  ACS instead suggests 
providers base their decision to vaccinate on the patient’s individual risk factors for 
previous HPV exposure and number of sexual partners.  Conflicting national 
guidelines reflect discordant opinions among health care providers about the public 
health and clinical benefits of vaccination for women who are already sexually active.  
Unvaccinated women are likely to be influenced by their providers’ opinions when 
making decisions about vaccination (Brewer & Fazekas, 2007; Hopfer & Clippard, 
2011).   A 2010 study of insured women aged 19-26 showed that women who received 
a physician’s recommendation for vaccination were more likely to be vaccinated 
(Rosenthal, 2010); further, a strong recommendation resulted in a 4-fold greater 
likelihood of vaccination than one that was not strong.  It is has been shown that 
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physicians who disagree that the vaccine can provide protective benefit to an older 
female do not recommend HPV vaccination and advise against it (Goff, Mazor, 
Schaffer, Corey, & Blake, 2011).  In our sample, 7% of women indicated their main 
reason for not receiving the vaccine was because their doctor did not recommend it.  
Zimet et al. (2010) found that 5% of 18-26 women did not initiate vaccination because 
their doctor recommended against it.  Further research is needed to examine the 
proportion of physicians who do not support adult HPV vaccination, or do not 
recommend it to their patients for other reasons. 
 In addition to multiple risk factors for non-vaccination status, we also found 
several factors to be protective against non-vaccination.  First, US census region of 
residence was found to have a protective effect against non-vaccination.  In univariate 
analyses, living in the Midwest or West was associated with increased odds of 
vaccination compared to those living in the South, but in multivariate analyses only 
living in the West was associated with increased odds of vaccination.  Recent research 
specific to geographic variability in HPV vaccine uptake has also demonstrated that 
18-26 year olds in the Midwest and West regions were more likely to be vaccinated 
than young women in the Northeast (Wei, Moore, & Green, 2013).  The authors 
believed geographic variability may be influenced by regional providers’ likelihood of 
recommending vaccine and by women’s knowledge and attitudes regarding HPV and 
HPV vaccines.  There is little other research to explain geographic variability, but a 
2010 study from CDC revealed HPV vaccine coverage to be lower among adolescent 
girls living in the Southeastern US compared to girls living in other regions (CDC, 
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2011b).  Further, areas with higher poverty rates may explain geographic variability; 
among girls in six US states, girls living in higher-poverty states were shown to be less 
likely to be vaccinated (Pruitt & Schootman, 2010).  
Healthcare utilization, or more specifically, health prevention behaviors, such 
as having had a doctor’s visit in the past year, current birth control, flu vaccine receipt, 
and tetanus vaccine receipt were also found to be protective factors.  In a recent 
review of HPV vaccine uptake among adolescent women, a study showed that 43% of 
adolescents who received HPV vaccine also received a second preventative health 
service (Etter, Zimet, & Rickert, 2012).  In univariate analyses in our study, having a 
usual place of care, or medical home, was a significant predictor of vaccine initiation.  
It is reasonable to assume that vaccinated, insured women with recent health care 
visits are engaging in other health care prevention behaviors such as pregnancy 
prevention and adherence to other recommended vaccines.    
Among the significant healthcare utilization predictors, receipt of flu vaccine 
in the past year was found to be the most protective factor.  Women who received a flu 
vaccine were almost three times as likely to have initiated the HPV vaccine series.  
Receipt of other vaccines has been shown to predict HPV vaccination behavior in 
other national probability samples.  For example, Jain et al., (2007) found that young 
women who were vaccinated against Hepatitis B were more likely to have received at 
least one dose of the HPV vaccine series.  Receipt of flu vaccine has also been shown 
to influence uptake of other vaccines such as Tdap (Miller, Kretsinger, Euler, Lu, & 
Ahmed, 2011).  Women who report receipt of multiple recommended vaccines may 
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have more confidence in vaccine safety and efficacy.  Further research is needed to 
better understand the variables that predict public confidence in vaccines.  Among 
unvaccinated women in this sample, concerns about not knowing enough about the 
vaccine and concerns about the safety of the vaccine emerged as the second and third 
most frequently reported reasons for non-vaccination.  These results reflect previous 
findings from young women who cited concerns about lack of sufficient information 
about the vaccine, and concerns about side-effects or the vaccine being too new 
(Zimet, 2010).  Addressing lack of public confidence in vaccines is emerging as a 
research priority to identify new interventions to increase vaccine coverage (Larson, 
Cooper, Eskola, Katz, & Ratzan, 2011).   Health communications campaigns may 
benefit from acknowledging lack of public confidence in vaccines, and working with 
target populations to develop vaccine messages that build public trust in vaccines.  
New messages are needed that communicate the excellent safety and efficacy record 
of both vaccines, while providing accurate information about risk-benefit ratio of 
vaccines.   Campaigns should direct unvaccinated individuals to objective (non-
industry) sources of vaccine safety information (such as the CDC or other trusted 
entity) so individuals are confident in their ability to make informed decisions about 
their personal risks and benefits of vaccination.   
Limitations 
 The current study has several limitations.  First, results are based on one cross-
sectional analysis and further examination of findings to predict non-vaccination will 
require longitudinal designs.  Second, NHIS relies exclusively on self-report measures 
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and is not confirmed by objective measures.  All self-report data are vulnerable to 
recall and misclassification bias and caution should be used when interpreting rates of 
vaccination and other data.   Third, the NHIS was restricted to noninstitutionalized 
civilian adults and generalization to the wider population cannot be inferred.  
Oversampling of ethnic and racial minority groups may inflate estimates relating to 
these groups.  Additionally, there is potential coverage bias or bias that exists for the 
exclusion of households without landline telephones (Blumberg & Luke, 2012).  For 
example, in comparative analyses between people with landline phone only and 
people with wireless phones only, wireless people tended to be older, in poverty, 
living in the Midwest, South, or West as compared to the Northeast, and Hispanic or 
Black.  Fifth, multivariate models required complete data on all variables used in the 
model and this reduced sample size, thereby potentially reducing the statistical power 
of the model.  Lastly, estimates were not weighted in SUDAAN to account for the 
complex sampling design.  
Implications 
Current findings contribute to previous research demonstrating disparities in 
vaccine uptake among 18-26 year old women.  While vaccine uptake in this age group 
has increased since 2007, young adults lag far behind adolescent girls aged 11-17 and 
it is unlikely optimal vaccine coverage targets will be met among this group unless 
evidence-based targeted programs are designed and implemented to address the 
variables known to predict non-vaccination.  Significant challenges exist in developing 
effective, scalable interventions to reach high-risk subgroups of adult women.  Many 
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variables significant in multivariate analyses can be considered “static” and not 
amenable to intervention.  Infrastructure and funding for adult vaccine uptake are 
lacking to adequately address structural barriers to vaccination, but vaccine promotion 
programs may benefit from further examination specific to HPV and HPV vaccine 
knowledge and attitudes, personal reasons for not receiving vaccination, and general 
public confidence in vaccines.  In the US, adult vaccine coverage (adults ≥19 years of 
age) of recommended vaccines continues to be low, and lower than objectives set for 
Healthy People 2020.  In addition to general public health practice recommendations 
of increased access to vaccines through non-traditional venues (e.g. pharmacies, 
workplaces, and community events), clinic reminder systems, and reduced financial 
barriers, programs of research to increase vaccine uptake may also benefit from 
interventions that aim to increase physician recommendation for vaccination, increase 
perceived risk for HPV without vaccine,  increase perceived benefit of the vaccine, 
and decrease inflated concerns about safety and side-effects.  
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Table 1. All Potential Predictors and Original Response Categories 
          
Race Recode 
White only, Black only, American Indian/Alaskan Native only, 
Asian only, Multiple Race, Not Released 
Race/Ethnicity    Hispanic, White, Non- Hispanic Black, Other  
Hispanic Ethnicity  Yes, No 
Marital Status  
Separated, Divorced, Married, Single/Never Married, Widowed, 
Unknown 
Born in US  Yes, No, Refused, Don't Know 
Language  Only Spanish, Mostly Spanish, Spanish and English, Mostly 
English, Only English, Other, Not Ascertained 
Region 
   
Northeast, Midwest, South, West 
Age  Continous 
Live birth within past 5 years Yes, No, Refused, Don't Know, Not Ascertained 
Medicaid  
Yes, Yes but no information, No, Refused, Don't Know, Not 
Ascertained 
Medicare  
Yes, Yes but no information, No, Refused, Don't Know, Not 
Ascertained 
State Children’s Health 
Insurance Program coverage 
Yes, Yes but no information, No, Refused, Don't Know, Not 
Ascertained 
State-sponsored health plan 
 
Yes, Yes but no information, No, Refused, Don't Know, Not 
Ascertained 
Other government health 
plan 
 
Yes, Yes but no information, No, Refused, Don't Know, Not 
Ascertained 
Military health care 
coverage 
 
Yes, Yes but no information, No, Refused, Don't Know, Not 
Ascertained 
Ineligible because of 
age/school 
 
Mentioned, Not Mentioned, Refused, Don't Know, Not 
Ascertained - 
Private Insurance  
Yes, Yes but no information, No, Refused, Don't Know, Not 
Ascertained 
No Coverage  Not covered, covered, refused, don't know, not ascertained 
Education  Less than 8th grade, 9th-12th grade, HS or GED, AA, some 
college, Bachelors, masters, doctoral, Refused, Don't Know, Not 
Ascertained  
Total earnings last year 
 
$0-4,999, $5,000-$9,999, $10,000-$14,999, $15,000-$19,999, 
$20,000-$24,999, $25,000-$29,999, $30,000-$34,999, $35,000-
$39,999, $40,000-$44,999, $45,000-$54,999, $55,000-$64,999, 
$65,000-$74,999, over $75,000, Refused, Don't Know, Not 
Ascertained 
Full time work  
  
Yes,No, Refused, Don't Know, Not Ascertained 
Pap test ever  
  
Yes,No, Refused, Don't Know, Not Ascertained 
Abnormal Pap test results -
past 3 years   
Yes,No, Refused, Don't Know, Not Ascertained 
  Told by doctor had HPV  
 
Yes,No, Refused, Don't Know, Not Ascertained 
Reported Health Status  
 
Excellent, Very Good, Good, Fair, Poor, Refused, Don't Know, 
Not Ascertained 
Has usual Place to go when 
sick   
Yes,No, Refused, Don't Know, Not Ascertained 
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Place to go when sick 
 
Doctor's office, clinic, hospital ER, hospital outpatient, some other 
place, doesn't go to one place, refused, don't know, not ascertained   
  Currently taking birth 
control pills, implants, or 
shots 
 
Yes,No, Refused, Don't Know, Not Ascertained
  Seen/talked to doctor in 
past 12 months   
Yes,No, Refused, Don't Know, Not Ascertained 
  Seen/talked to OB/GYN in 
past 12 months   
Yes,No, Refused, Don't Know, Not Ascertained
 
Yes,No, Refused, Don't Know, Not Ascertained 
Flu shot past 12 months  
 
Yes,No, Refused, Don't Know, Not Ascertained 
Hepatitis A vaccine - ever 
(Y,N) 
 
Yes,No, Refused, Don't Know, Not Ascertained 
Hepatitis B vaccine - ever 
(Y,N) 
 
Yes,No, Refused, Don't Know, Not Ascertained 
Tetanus shot in past 10 
years (Y,N) 
 
Yes,No, Refused, Don't Know, Not Ascertained 
Had STD past 5 years  
 
Yes,No, Refused, Don't Know, Not Ascertained 
Saw a doctor for STD  
 
Yes,No, Refused, Don't Know, Not Ascertained 
Ever been tested for HIV 
(Y,N) 
 
Yes,No, Refused, Don't Know, Not Ascertained 
Heard of HPV  
 
Yes,No, Refused, Don't Know, Not Ascertained 
Heard of HPV vaccine/shot  Yes,No, Refused, Don't Know, Not Ascertained 
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Table 2. Selected Sample Characteristics of non-vaccinated women (n=1,458)* 
Characteristic N %     
  Age 
         18-20 322 22.1 
       21-23 528 36.2 
       24-26 608 41.7 
    Insurance Coverage 
          Yes 1041 75.4 
        No 412 28.3 
    Married  
          Yes 315 21.6 
        no  1140 78.2 
    Race/ethnicity 
         Hispanic 366 24.0 
       non-Hispanic white 685 46.9 
       non-Hispanic black 296 20.3 
       non-Hispanic other  111 7.6 
    Region 
         Northeast 188 12.9 
       Midwest 325 22.3 
       South 566 38.8 
       West  379 25.7 
    Education 
          Less than high school 242 16.6 
        High school 377 25.9 
        Some college 576 39.6 
        College or higher 260 17.9 
    Annual Income 
          0-19,999 759 52.1 
        20,000-34,999 241 16.5 
         ≥35,000 116 8.0 
    Given birth in past 5 years  
          Yes 540 37.0 
        no  918 62.9 
    Currently on birth control  
          Yes 452 31.0 
        no  999 68.5 
    Ever had Pap test  
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    Yes 1139 78.1 
        no  312 21.4 
    Seen a doctor in past year 
        Yes 785 53.8 
      No 672 46.1 
    Flu shot last 12 months  
         Yes 159 17.6 
       No 744 82.5 
    Tetanus shot last 10 years 
         Yes 871 59.7 
       No 535 36.7 
    Hepatitis A vaccine  
          Yes 345 23.7 
        no  927 63.6 
    Hepatitis B vaccine  
          Yes 805 55.2 
        No 556 38.1 
    * Some totals may not add up to 100% due to missing responses to deleted categories  
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Table 3.  HPV Vaccine Attitudes and Awareness of Non-Vaccinated Women*  
Question n %   
Heard of HPV (n=1458) 
       Yes 1089 74.7 
     No 368 25.2 
 Heard of HPV vaccine (n=1458) 
       Yes 954 65.4 
     No 504 34.6 
 Interested in getting HPV vaccine (n=1458) 
       Yes 480 32.9 
     No 917 62.9 
 Would get vaccine if the cost was $360-500 (n=408) 
       Yes 96 20.0 
     No 377 78.5 
 Would get vaccine if free or lower cost (n=404) 
       Yes 386 95.5 
     No 11 2.7 
 Main reason would not get HPV vaccine (n=988) 
      does not need vaccine 395 40.4 
    not sexually active 70 7.20 
    too expensive 27 2.8 
    too old for vaccine 28 2.9 
    doctor didn't recommend it 76 7.8 
    worried about safety of vaccine 106 10.8 
    don't know where to get vaccine 3 0.3 
    my spouse/family member is against it 4 0.4 
    don’t know enough about the vaccine 132 13.5 
    already have HPV 25 2.6 
 * Some totals may not add up to 100% due to missing responses         
   or deleted categories    
   
 
 
 
 
  
 
 
 
  
40 
 
Table 4. Selected Sample Characteristics of Vaccinated Women (n=408)* 
Characteristic N %     
 Age 
        18-20 170 41.6 
      21-23 135 33.1 
      24-26 103 25.2 
   Insurance Coverage 
         Yes 340 83.9 
       No 65 16.1 
   Married  
         Yes 45 11.03 
       no  363 88.9 
   Race/ethnicity 
        Hispanic 82 20.1 
      non-Hispanic white 230 56.3 
      non-Hispanic black 71 17.4 
      non-Hispanic other  25 6.1 
   Region 
        Northeast 54 13.2 
      Midwest 108 26.4 
      South 129 31.6 
      West  117 28.6 
   Education 
         Less than high school 46 11.2 
       High school 82 48.2 
       Some college 197 48.2 
       College or higher 83 20.3 
   Annual Income 
         0-19,999 180 61.4 
       20,000-34,999 47 16.0 
        ≥35,000 66 22.5 
   Given birth in past 5 years  
         Yes 82 20.1 
       no  326 79.9 
   Currently on birth control  
         Yes 205 50.3 
       no  202 49.6 
   Ever had Pap test  
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    Yes 332 81.5 
       no  75 18.4 
   Seen a doctor in past year 
       Yes 291 71.3 
     No 117 28.6 
   Flu shot last 12 months  
        Yes 78 37.1 
      No 132 62.8 
   Tetanus shot last 10 years 
        Yes 317 81.2 
      No 73 18.7 
   Hepatitis A vaccine  
         Yes 152 43.1 
       no  201 56.9 
   Hepatitis B vaccine  
         Yes 263 75.4 
       No 92 24.5 
   * Some totals may not add up to 100% due to missing responses to deleted categories  
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Table 5. Summary of Bivariate Associations between Potential  
     Predictors and Non-vaccination 
     Variable Grouping p value 
               
     Demographic Variables   
     Race Recode (white, not white) 0.048* 
     Race/Ethnicity (Hispanic, White, Non-  
Hispanic Black, Other)    
0.0098* 
  Hispanic Ethnicity (Yes, No) 0.0369* 
     Marital Status (Married, not married) <.0001* 
     Born in US (Y,N) 0.0057* 
     Language (English, Other) 0.0006* 
     Region 
   
0.0519* 
     Age  <.0001* 
     Live birth within past 5 years <.0001* 
     
       Socioeconomic Variables   
     Medicaid (Y,N)  0.0448* 
     Medicare   - 
     SCHIP coverage  - 
     State-sponsored health plan 
 
 - 
     Other government health 
plan 
 
 - 
     Military health care 
coverage 
 
 - 
     Ineligible because of 
age/school 
 
 - 
     Private Insurance (Y,N) <.0001* 
     No Coverage (Y,N)  <.0001* 
     Education (<HS, HS, some college, 
≥college)     
0.0006* 
     
      College Education (Y, N) <.0001* 
     Total earnings last year 
 
0.3522 
     Full time work (Y,N)  
 
 - 
     
          Health Utilization      
     Pap test ever (Y, N) 
  
0.177* 
     Abnormal Pap test results -
past 3 years (Y, N)  
0.0761* 
     
       Told by doctor had HPV 
 
0.0022*
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(Y,N) 
Reported Health Status 
(Excellent/Very good vs. 
Good/Fair/Poor) 
 
0.2602 
     
       Has usual Place to go when 
sick (Y, N) 
 
<.0001* 
     Place to go when sick 
(doctor's office/clinic vs. 
other) 
 
0.8058 
     
       Currently taking birth 
control pills, implants, or 
shots (Y,N) 
 
<.0001*
     
       Seen/talked to doctor in past 
12 months (Y,N)  
<.0001*
     
       Seen/talked to OB/GYN in 
past 12 months (Y,N)  
0.2211*
     
       Flu shot past 12 months 
(Y,N) 
 
<.0001* 
     Hepatitis A vaccine - ever 
(Y,N) 
 
<.0001* 
     Hepatitis B vaccine - ever 
(Y,N) 
 
<.0001* 
     Tetanus shot in past 10 years 
(Y,N) 
 
<.0001* 
     Had STD past 5 years (Y,N) 
 
0.1062* 
     Saw a doctor for STD (Y,N) 
 
 - 
     Ever been tested for HIV 
(Y,N) 
 
0.2711 
     
        Knowledge  
     Heard of HPV (Y, N) 
 
<.0001 
     Heard of HPV vaccine/shot 
(Y,N)     - 
     * variables significant at exploratory level of p<.20 
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Table 10. Full Model (N=1,041; no=846, yes=195) 
Variable aOR 95% CI p SE 
Age  
      18-21 (ref) 
      22-25 3.39 2.26-5.09 <.0001 0.20 
  26 1.82 1.01-3.28 0.045 0.30 
Marital Status 1.83 1.04-3.21 0.036 0.28 
No insurance 1.60 0.97-2.62 0.061 0.25 
College education 0.69 0.46-1.05 0.0867 0.21 
Region  
      South (ref) 
      Northeast 0.64 0.36-1.13 0.1305 0.28 
  Midwest 0.64 0.39-1.03 0.0697 0.24 
  West 0.48 0.30-0.77 0.0027 0.24 
Usual place of care 0.78 0.47-1.31 0.3594 0.26 
Live birth in past 5 years 2.62 1.59-4.29 0.0001 0.25 
Currently on birth control 0.46 0.32-0.66 <.0001 0.18 
Doctor visit past 12 months 0.64 0.42-0.97 0.0352 0.20 
Flu shot in past year 0.35 0.23-0.52 <.0001 0.20 
Tetanus shot in past 10 years 0.44 0.28-0.69 0.0004 0.23 
model chi-square (LR)=213.55 (14), p=<.0001 
   Hosmer-Lemeshow chi square=7.84 (8), p=.448 
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Table 11: Final Model  (N=1067; no=868, yes=199) 
Variable aOR 95% CI p SE 
Age  
      18-21 (ref) 
      22-25 2.93 2.00-4.30 <.0001 0.19 
  26 1.49 0.85-2.61 0.156 0.28 
Married 1.75 1.02-3.01 0.042 0.27 
Region  
      South (ref) 
      Northeast 0.65 0.38-1.14 0.136 0.27 
  Midwest 0.65 0.41-1.04 0.077 0.23 
  West 0.50 0.31-0.79 0.003 0.23 
Live birth in past five years 2.77 1.75-4.39 <.0001 0.23 
Currently on birth control  0.45 0.31-0.64 <.0001 0.17 
Doctor visit past year 0.57 0.39-0.84 0.0045 0.19 
Flu shot in past year 0.36 0.24-0.54 <.0001 0.20 
Tetanus shot in past 10 years 0.40 0.26-0.62 <.0001 0.22 
model chi-square (LR)=193.30 (11), p=<.0001 
  Hosmer-Lemeshow chi square=14.41(8), p=.071 
  Max Rescaled R-square=0.268 
  Percent Concordant=79.1 
  Percent Discordant=20.2 
    c=.795 
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Table 14: Backwards Elimination Procedure (N=1,063; no=864, yes=199) 
Variable aOR 95% CI p SE 
Not covered 1.70 1.06-2.72 0.027 0.24 
Age  
      18-21 (ref) 
      22-25 2.91 1.99-4.27 <.0001 0.19 
  26 1.51 0.86-2.65 0.14 0.28 
Married 1.81 1.06-3.17 0.028 0.27 
Region  
      South (ref) 
      Northeast 0.68 0.39-1.18 0.175 0.28 
  Midwest 0.67 0.42-1.07 0.099 0.23 
  West 0.49 0.31-0.78 0.002 0.23 
Live birth 2.67 1.69-4.23 <.0001 0.23 
birth control pills 0.46 0.32-0.61 <.0001 0.17 
doctor visit past year 0.63 0.43-0.93 0.021 0.02 
Flu shot 0.36 0.24-0.54 <.0001 0.20 
Tetanus shot 0.42 0.27-0.66 0.0002 0.22 
model chi-square (LR)=198.05 (12), p=<.0001 
  Hosmer-Lemeshow chi square=10.24(8), p=.247 
  Max Rescaled R-square=0.27 
  Percent Concordant=79.3 
  Percent Discordant=20.0 
    c=.797 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
53 
 
 
 
 
 
 
 
  
 
 
 
  
54 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
55 
 
Table 17.  2011 Cross-Validation Model (N=2,220; no=1568, yes=639) 
Variable aOR 95% CI p SE 
Age  
      18-24 (ref) 
      25 1.61 1.19-2.19 .0021 0.15 
  26 2.42 1.70-3.43 <.0001 0.17 
Married 2.38 1.78-3.19 <.0001 0.14 
Region  
      South (ref) 
      Northeast 0.55 0.41-0.75 .0002 0.15 
  Midwest 0.78 0.61-1.01 0.06 0.12 
  West 0.78 0.60-1.00 0.05 0.12 
Doctor visit past year 0.62 0.51-0.77 <.0001 0.10 
Flu shot in past year 0.60 0.49-0.75 <.0001 0.11 
Tetanus shot in past 10 years 0.46 0.36-0.58 <.0001 0.10 
model chi-square (LR)=222.86 (11), p=<.0001 
  Hosmer-Lemeshow chi square=2.80(8), p=.94 
  Max Rescaled R-square=0.137 
  Percent Concordant=68.6 
  Percent Discordant=29.2 
    c=.696 
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Figure 1: Odds Ratio Plot for Age 
 
 
 
Odds Ratio Estimates 
Effect 
Point 
Estimate 
95% Wald 
Confidence 
Limits 
AGE_P 19 vs 
18 
1.295 0.816 2.054 
AGE_P 20 vs 
18 
1.166 0.738 1.842 
AGE_P 21 vs 
18 
1.651 1.042 2.614 
AGE_P 22 vs 
18 
3.06 1.878 4.986 
AGE_P 23 vs 
18 
2.668 1.686 4.222 
AGE_P 24 vs 
18 
3.804 2.308 6.27 
AGE_P 25 vs 
18 
4.565 2.726 7.645 
AGE_P 26 vs 
18 
2.803 1.755 4.476 
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Figure 2: ROC Curve Final Model  
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Figure 3: ROC Curve Backwards Elimination Model  
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Figure 4: ROC Curve 2011 Cross-Validation Model  
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